[1] ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128. doi:  10.1056/NEJMoa1504720
[2] NEAL B, PERKOVIC V, MAHAFFEY K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657. doi:  10.1056/NEJMoa1611925
[3] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357. doi:  10.1056/NEJMoa1812389
[4] CANNON C P, PRATLEY R, DAGOGO-JACK S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med,2020,383(15):1425-1435. doi:  10.1056/NEJMoa2004967
[5] PERKOVIC V, JARDINE M J, NEAL B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med,2019,380(24):2295-2306. doi:  10.1056/NEJMoa1811744
[6] MARSO S P, DANIELS G H, BROWN-FRANDSEN K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-322. doi:  10.1056/NEJMoa1603827
[7] MARSO S P, BAIN S C, CONSOLI A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844. doi:  10.1056/NEJMoa1607141
[8] HOLMAN R R, BETHEL M A, MENTZ R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2017,377(13):1228-1239. doi:  10.1056/NEJMoa1612917
[9] PFEFFER M A, CLAGGETT B, DIAZ R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med,2015,373(23):2247-2257. doi:  10.1056/NEJMoa1509225
[10] HERNANDEZ A F, GREEN J B, JANMOHAMED S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial[J]. Lancet,2018,392(10157):1519-1529. doi:  10.1016/S0140-6736(18)32261-X
[11] GERSTEIN H C, COLHOUN H M, DAGENAIS G R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J]. Lancet,2019,394(10193):121-130. doi:  10.1016/S0140-6736(19)31149-3
[12] HUSAIN M, BIRKENFELD A L, DONSMARK M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2019,381(9):841-851. doi:  10.1056/NEJMoa1901118
[13] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4):311-398. doi:  10.3760/cma.j.cn311282-20210304-00142
[14] 赖彦岚, 黄爱文, 张丽丽, 等. SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展[J]. 药学实践杂志, 2020, 38(6):496-500,567. doi:  10.12206/j.issn.1006-0111.202006061
[15] 杨智荣, 孙凤, 詹思延. 偏倚风险评估系列: (二)平行设计随机对照试验偏倚评估工具2. O介绍[J]. 中华流行病学杂志, 2017, 38(9):1285-1291. doi:  10.3760/cma.j.issn.0254-6450.2017.09.028
[16]

SPIEGELHALTER D J, BEST N G, CARLIN B P, et al. Bayesian measures of model complexity and fit[J]. J Royal Stat Soc Ser B Stat Methodol,2002,64(4):583-639. doi:  10.1111/1467-9868.00353
[17]

VERONIKI A A, VASILIADIS H S, HIGGINS J P T, et al. Evaluation of inconsistency in networks of interventions[J]. Int J Epidemiol,2013,42(1):332-345. doi:  10.1093/ije/dys222
[18]

SALANTI G, ADES A E, IOANNIDIS J P A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial[J]. J Clin Epidemiol,2011,64(2):163-171. doi:  10.1016/j.jclinepi.2010.03.016
[19]

CHAIMANI A, HIGGINS J P, MAVRIDIS D, et al. Graphical tools for network meta-analysis in STATA[J]. PLoS One,2013,8(10):e76654. doi:  10.1371/journal.pone.0076654